Michael Garshick is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
530 1st Ave Ste 4f
New York, NY 100166402
Telephone
212-263-0855Provider last certified this registry record 11 Mar 2021.
Clinical trials
- A Clinical Trial of Antiplatelets in Psoriasis
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- ARGENX US, INC.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.9%Statin26.6%Atorvastatin Calcium77%Rosuvastatin Calcium23%Part D≥47 patientsPCSK9 Inhibitor15.5%Repatha Sureclick72%Repatha Pushtronex15%Praluent Pen13%Part D<11 patients+ 6 more classes in this area
Cancer & immunology
7.5%Interleukin inhibitors7.5%Arcalyst100%Part D<11 patientsBlood & clotting
5.9%Factor Xa inhibitor5.9%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Testing various antiplatelet strategies in psoriasis to improve vascular health
New York University School of Medicine
FY2026$845,590R01HL188015 - Endovascular Health and Platelet Activity in Psoriasis
New York University School of Medicine
FY2025$171,789K23HL152013 - Endovascular Health and Platelet Activity in Psoriasis
New York University School of Medicine
FY2024$172,424K23HL152013
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”